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1008 Original ResearchBACKGROUND: Diagnosis of primary ciliary dyskinesia (PCD) relies on a combination of
tests. High-speed video microscopy analysis (HSVA) is widely used to contribute to the
diagnosis. It can be analyzed on the day of diagnostic consultation, but the qualitative
analyses are subjective. Diagnostic accuracy and reliability of assessing ciliary function
have not been robustly evaluated. We aimed to establish the accuracy of HSVA to di-
agnose PCD compared with a combination of tests, and to assess the interobserver
reliability of HSVA analysis.
METHODS: We randomly selected and anonymized archived videos from 120 patients seen at
three UK PCD centers. Three experienced scientists independently reviewed six videos per
patient, using a standardized proforma, blinded to diagnostic and clinical data. We compared
study outcomes with two references: (1) a combination of diagnostic tests in accordance with
the European Respiratory Society PCD diagnostic guidelines and (2) original clinical
outcome determined by all available diagnostic tests.
RESULTS: HSVA had excellent sensitivity and specificity to diagnose PCD: (1) 100% and 96%,
respectively, compared with ERS guidelines, and (2) 96% and 91% compared with diagnostic
outcomes. There was high interobserver agreement for “PCD-positive” outcomes (k ¼ 0.7).
CONCLUSIONS: Specialist scientists accurately diagnosed PCD using HSVA, with high
interobserver agreement. HSVA can be reliably used to counsel patients and commence
treatment on the day of testing while awaiting confirmatory investigations.
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Primary ciliary dyskinesia (PCD) is a rare (?1:10,000-
20,000), heterogeneous disease, usually inherited as an
autosomal recessive condition. Impaired function of motile
cilia leads to neonatal respiratory distress in term infants,
persistent wet cough, bronchiectasis, chronic rhinosinusitis,
fertility issues, and conductive hearing impairment.
Approximately 50% of patients have situs inversus, and
congenital heart disease has been reported in 5% of
children.1
In the absence of a single “gold standard” test, guidelines
recommended that diagnosis requires access to a number
of tests.2,3 In our centers, a multidisciplinary team (MDT)
of clinical and laboratory staff determines whether patients
have PCD using clinical history, nasal nitric oxide (nNO),
high-speed video microscopy analysis (HSVA),
transmission electron microscopy (TEM), and more
recently air-liquid interface (ALI) cell culture,
immunofluorescence, and genetic analysis.4 TEM can
confirm a diagnosis, but is normal in 15% to 20% of
patients with PCD and therefore cannot be used to exclude
a diagnosis.2,5,6 Similarly, poor sensitivity (?0.65) means
that genotyping cannot be used in isolation, but pathogenic
biallelic mutations in known genes confirm a diagnosis.7,8and University Hospital Southampton NHS Foundation Trust,
Southampton, UK.
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chestjournal.orgHSVA is a technique where the respiratory cilia are
visualized ex vivo with a light microscope, and recorded
with a high-speed video camera. Videos are assessed for
multiple parameters including ciliary beat frequency, ciliary
beat pattern (CBP), and effective mucociliary clearance.
HSVA is the only widely used test that assesses ciliary
function, and results are available on the day of testing. In
comparison, TEM and genetic analyses may take weeks or
even months to get a definitive result. HSVA is used
frequently at European and Australian PCD centers, but
less so in North America.2,3 Previous retrospective studies
have suggested high sensitivity and specificity of HVSA as
a diagnostic test9,10; however, both studies risked bias due
to study design.11 In addition, there has never been a study
to assess the intra- and interobserver agreement of HSVA.
If confirmed to be accurate, with good reliability, clinicians
could make informed decisions on whether to initiate
treatment on the day of a patient’s clinic appointment
whilst awaiting TEM and genetics results, reducing time to
diagnosis and potentially limiting disease progression.
We hypothesized that (1) scientists using HSVA would
accurately diagnose PCD and (2) there would be good
interobserver reliability of the test.Materials and Methods
Local and national research and ethics approvals were adhered to
(Southampton and SouthWest Hampshire Research Ethics 07/Q1702/109).
Patient Population and Diagnostic Decisions in the Clinical
Setting
Patients were referred to one of three UK PCD diagnostic centers
between January 2015 and April 2017. Testing included acombination of clinical history, nNO, HSVA, and TEM. With
selected cases, we additionally included reanalysis following ALI
culture and immunofluorescence staining; genetic testing was
conducted on selected patients for research. For HSVA, diagnostic
scientists report the sample to be compatible with PCD, unlikely to
be PCD, or inconclusive; they base this decision on analysis of at
least six videos from the same sample, including five side views and
one top view. Investigations are detailed in e-Table 1. Teams from
the three centers share diagnostic protocols and frequently discuss
difficult cases.
Diagnostic results were reviewed at MDT meetings, including a
clinician, HSV microscopist, and TEM technician. All clinical and
diagnostic data were considered when agreeing on the MDT
diagnostic outcome as “PCD positive,” “PCD highly likely,” “PCD
highly unlikely,” or “inconclusive,” based on clinical experience. An
inconclusive diagnosis was reported when abnormalities not
attributed to secondary defects were seen after repeated testing of
adequate samples, but not sufficiently or consistently throughout the
repeat testing to be deemed “PCD highly likely,” or when further
testing was still needed to rule in or rule out a PCD diagnosis.
Selection of Reference Standards
There is no “gold standard” reference for PCD diagnostics, and we
therefore compared the scientists’ study outcomes with two
imperfect references12: (a) outcomes defined using European
Respiratory Society (ERS) guidelines for the diagnosis of PCD2 (Fig
1A); and (b) the clinical MDT outcome for the patient, extracted
from contemporary MDT meeting reports (Fig 1B). For reference a,
diagnostic test results were retrospectively used to define the patient
outcome as “PCD positive” or “PCD highly unlikely.” Both “PCD
highly likely” and “inconclusive” outcomes were considered as
indeterminate for accuracy calculations, as they do not provide a1009
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Figure 1 – The two reference standards used to assess the accuracy of high-speed video microscopy (HSVA) analysis. A, ERS guidelines recommended a
standardized terminology to describe the diagnostic outcome.2 If the patient has a hallmark transmission electron microscopy (TEM) defect or biallelic
or X-linked causative mutation in a primary ciliary dyskinesia (PCD) gene, they are diagnosed as “PCD positive.” If nasal nitric oxide (nNO) is
repeatedly low and hallmark HSVA alterations are found on three separate occasions or after air-liquid interface (ALI) cell culture, but TEM and
genetics testing are normal, the patient is labeled as “PCD highly likely”; PCD is considered “highly unlikely” if all tests produce normal results. Despite
repeated testing, the diagnostic category for a proportion of patients remains inconclusive; these were patients who did not satisfy the criteria to be
included in any of the other categories. B, In the clinical setting, all available clinical and diagnostic data were reviewed at a multidisciplinary meeting
to define the diagnostic outcome, based on the opinion of the expert team. ERS ¼ European Respiratory Society.definitive outcome.2 Patients with diagnostic test results that did not
fulfill criteria for “PCD positive,” “PCD highly likely,” or “PCD
highly unlikely” were deemed “inconclusive.” The strength of using
this reference is that it follows an evidence-based international
guideline, and that the “PCD positive” outcome is based only on
“hallmark” TEM and/or pathogenic biallelic mutations in PCD
genes, and therefore does not include HSVA in the reference
standard. TEM and genetics are believed to have excellent specificity
(?1.0), but the limitation is that both tests have poor sensitivity (0.8
and 0.7, respectively) and will therefore “miss” a significant
proportion of patients with true PCD. Moreover, genotyping was
undertaken only in a small subset of patients, as it is not readily
available in the English National Health Service (NHS).
For reference b, diagnostic outcomes were extracted from the
contemporary clinical MDT meeting reports. The strength of using
this reference is that it was based on all data available to an expert
MDT at the time of the meeting and it represents a clinical decision1010 Original Researchon how to manage patients; however, the limitation is that HSVA is
included in the reference.
Analysis of Archived Videos
One hundred and twenty patients were randomly selected for inclusion
in the study. Inclusion and exclusion criteria for sample selection are
detailed in the online article (e-Appendix 1, e-Fig 1).
Clinical data were extracted from local clinical databases: clinical
symptoms, nNO results, TEM, genetic analysis (where available), and
final diagnostic outcome by MDT decision. Images were anonymized
and uploaded to a central platform. The HSVA scientists were not
aware of the study period and were not involved in data extraction
or uploading.
Three scientists, each with over 8 years of experience in HSVA, one
from each UK PCD diagnostic center, independently viewed 720
videos from 120 anonymized patient samples (six videos per sample,[ 1 5 5 # 5 CHE ST MA Y 2 0 1 9 ]
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Figure 1 – Continuedaccording to the UK standard diagnostic protocol). Scientists scored
the collection of six videos derived from each sample, blinded to
other clinical or diagnostic data, to provide an a priori study
outcome for each patient sample: “PCD positive,” “PCD highly
likely,” “PCD highly unlikely,” or “inconclusive,” based on qualitative
assessment of CBP and observed normality and abnormality in the
samples analyzed. To calculate the intraobserver agreement after 1
year, each of the three scientists independently, and blinded to their
initial assessment, reassessed 20 patient samples that were randomly
selected.13 We applied the same proportions of positive, negative,
and inconclusive cases used in the selection of the original study
sample (ie, 50%, 30%, and 20%, respectively).
Statistical Analyses
We stratified the total number of patients referred to each center during
the study period by their clinical diagnostic outcome, based on the MDT
final report: PCD positive (included PCD highly likely cases), PCD
highly unlikely, and inconclusive. We used disproportional sampling in
order to enhance the proportion of PCD-positive cases and obtain
sufficient data on subgroups of interest.14,15 Therefore 50% of our total
cohort were randomly sampled from the PCD positive or PCD highly
likely strata, 30% from the PCD highly unlikely stratum, and
20% from the inconclusive stratum. The sample size needed to detect
a sensitivity of 90% with  0.9% confidence intervals was 90 patient
samples.
To allow for missing data and indeterminate outcomes we randomly
selected 120 patients from each outcome stratum: 59 “PCD positive,”chestjournal.org36 “PCD highly unlikely,” and 25 “inconclusive.” Randomization for
each stratum was performed in STATA (StataCorp).
To calculate the accuracy of HSVA, we compared the outcomes by
each of the scientists with the patient reference outcome, using
reference a (the ERS guidelines) and reference b (the original MDT
report). For reference a, we defined true positive as [“PCD positive”
by scientist] divided by [“PCD positive” by reference]. Similarly, true
negative was defined as [“PCD highly unlikely” by scientist] divided
by [“PCD highly unlikely” by reference]. For reference b, we grouped
“PCD positive” and “PCD highly likely” outcomes, since these are
clinically managed similarly, and the “PCD highly likely” group is
likely to include patients with true PCD with normal TEM where
the genotype has not yet been resolved (Fig 2). True positive was
therefore defined as [“PCD positive” or “PCD highly likely” by
scientist] divided by [“PCD positive” or “PCD highly likely” by
MDT decision]. True negatives were defined as described for
reference a. For both references, false positive or false negative was
determined when HSVA scientists did not agree with reference.
We calculated the interobserver repeatability using the Fleiss k
coefficient for each diagnostic outcome.16 We calculated the
intraobserver repeatability for each of the scientists using the Cohen
k coefficient, with bootstrapped confidence intervals (n ¼ 5).17
Data were analyzed in STATA version 14.0. Continuous variables are
presented as median and interquartile range (IQR), and categorical
variables are reported as proportions. Sensitivity and specificity are
presented with 95% CIs, where appropriate. We report on both1011
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Figure 2 – Diagnostic algorithms used to determine true positive and true negative outcomes for test accuracy calculations, according to the ERS
guidelines (top half) and the clinical diagnostic decision by the multidisciplinary team (MDT) (bottom half). PCD ¼ primary ciliary dyskinesia. See
Figure 1 legend for expansion of other abbreviation.aggregate and individual (ie, each scientist) sensitivity and specificity of
HSVA study outcomes compared with both reference standards. We
obtained three outcomes for each sample: one from each scientist.
To adjust for clustering of data and to provide robust confidence
intervals, we used a generalized estimating equation (GEE) model
when reporting on all aggregate diagnostic outcomes.181012 Original ResearchTo deal with “inconclusive” study outcomes, test accuracy was also
calculated using the “worst-case scenario” approach, where
“inconclusive” were recoded as either “false positives” or “false
negatives” and adjusted for clustering using GEE modeling. Results
are reported according to the STARD (Standards for the Reporting
of Diagnostic Accuracy Studies) 2015 guidelines.19Results
The three diagnostic centers received a total of 1,286
referrals from January 2015 to April 2017; 115 were PCD
positive after review by the MDT, 852 were negative, and
305 were inconclusive. Thirteen nasal brushing samples
were deemed insufficient for analysis. Characteristics of the
patients whose videos were randomly selected for the study
are outlined in Table 1. Clinical characteristics extracted
were based on PICADAR, a PCD-specific diagnostic
predictive tool.20 Genetic results were available for 16
patients, of whom eight showed biallelic pathogenic
mutations in a PCD-causative gene (three in DNAH5, two
in DNAH11, two in CCDC40, one in RSPH9) and one in
an X-linked PCD gene (OFD1).
Accuracy of HSVA Compared With the ERS-Defined
Outcomes (Reference a)
Using the ERS PCD diagnostic guidelines, 36 patient
samples were “PCD positive,” 16 were “PCD highlylikely,” 26 were “PCD highly unlikely,” and 42 were
“inconclusive” (e-Table 2).
There was excellent sensitivity (100%) and specificity
(96.2%; 95% CI, 91.7%-100%) when comparing the
study decisions of HSVA scientists with the diagnostic
outcome based on outcomes defined by the ERS PCD
guidelines (Table 2). Specificity results were adjusted for
clustering; however, it was not possible to adjust
sensitivity as there were no “false negatives” observed. A
“worst-case scenario” combined with GEE modeling
showed that sensitivity remained high (93.3%; 95% CI,
92.0%-100%) but that specificity decreased from
96.2% to 67.9% (95% CI, 58.7%-77.2%).
Individual scientists had similarly good accuracy
(e-Table 2). A proportion of sampleswas reported as “highly
likely” or “inconclusive” when using either study HSVA
results alone or the ERS guidelines, and these outcomes
could not be included in the accuracy calculations.[ 1 5 5 # 5 CHE ST MA Y 2 0 1 9 ]
TABLE 1 ] Clinical Characteristics of Study Participants Stratified by Diagnostic Outcome According to European
Respiratory Society Guidelines
Characteristic
All Patients PCD Positive PCD Highly Likely
PCD Highly
Unlikely Inconclusive
(n ¼ 120) (n ¼ 36) (n ¼ 16) (n ¼ 26) (n ¼ 42)
Center for diagnostic
tests
UHS 40 (33.3%) 11 (30.6%) 3 (18.8%) 14 (53.9%) 12 (28.6%)
RBH 40 (33.3%) 12 (33.3%) 3 (18.8%) 3 (11.5%) 22 (52.4%)
LRI 40 (33.3%) 13 (36.1%) 10 (60.5%) 9 (34.6%) 8 (19.1%)
Age, y (median, IQR) 9.6 (2.8-16.7) 9.1 (3.0-20.9) 11.8 (8.9-12.6) 10 (2.0-29.5) 7.3 (2.9-14.8)
Preterm gestation 9 (8.9%) 0 3 (23.1%) 3 (14.3%) 3 (8.1%)
Chest symptoms in
neonatal period
97 (82.9%) 26 (78.8%) 15 (93.8%) 18 (69.2%) 38 (90.5%)
Admission to
neonatal unit
45 (41.3%) 17 (53.1%) 11 (78.6%) 7 (26.9%) 10 (27.0%)
Presence of situs
abnormalities
22 (18.6%) 16 (45.7%) 3 (18.8%) 0 3 (7.3%)
Cardiac abnormality 5 (4.3%) 1 (2.9%) 0 3 (11.5%) 1 (2.5%)
Persistent perennial
rhinitis
85 (72%) 28 (80.0%) 14 (93.3%) 13 (50.0%) 30 (71.4%)
Chronic ear or
hearing
symptoms
70 (60.3%) 20 (57.1%) 13 (86.7%) 13 (50.0%) 24 (60.0%)
nNO, nL/min, median
(IQR); No. for
whom data
available
21.8
(7.2-105.0);
n ¼ 72
9.8
(4.8-15.9);
n ¼ 22
7.2
(3.0-63.6);
n ¼ 11
189.2
(69.2-218.0);
n ¼ 11
72.3
(19.9-117.8);
n ¼ 28
TEM results
Normal 63 (52.5%) 2 (5.6%)a 7 (43.8%) 19 (73.1%) 35 (83.3%)
ODA alone 14 (11.7%) 13 (36.1%) 1 (6.25%)b 0 0
ODA þ IDA 14 (11.7%) 14 (38.9%) 0 0 0
IDA alone 4 (3.3%) 0 4 (25.0%) 0 0
MTD þ IDA 5 (4.2%) 5 (13.9%) 0 0 0
CC 5 (4.2%) 1 (2.8%)c 4 (25.0%) 0 0
Lack of cilia 2 (1.7%) 0 0 0 2 (4.8%)
Inconclusive 3 (2.5%) 1 (2.8%)d 0 0 2 (4.8%)
Not done 10 (8.3%) 0 0 7 (26.9%) 3 (7.1%)
CC ¼ central complex defect; ERS ¼ European Respiratory Society; IDA ¼ inner dynein arm defect; IQR ¼ interquartile range; LRI ¼ Leicester Royal
Infirmary; MTD ¼ microtubular disarrangement; nNO ¼ nasal nitric oxide; ODA ¼ outer dynein arm defect; PCD ¼ primary ciliary dyskinesia; RBH ¼
Royal Brompton Hospital in London; TEM ¼ transmission electron microscopy; UHS ¼ University Hospital Southampton.
aBiallelic mutations in the DNAH11 gene.
bTEM abnormality described as “thin ODA present,” not a hallmark PCD defect according to the ERS guidelines.
cBiallelic mutations in the RSPH9 gene.
dX-linked mutation in the OFD1 gene.Accuracy of HSVA Compared With MDT Decision
(Reference b)
Using the MDT diagnostic outcome as the reference
standard, 59 patients were “PCD positive,” 36 “PCD
highly unlikely,” and 25 had inconclusive test results
(e-Table 3). There was excellent sensitivity (96.7%;
95% CI, 92.9%-100%) and specificity (91.1%; 95% CI,chestjournal.org85.3%-96.9%) of study HSVA analysis compared with
the original MDT diagnostic outcome (Table 3).
Sensitivity dropped to 85.3% (95% CI, 78.0%-92.6%) and
specificity to 67.6% (95% CI, 58.4%-76.8%) when
calculating accuracy using the “worse-case” approach.
Individual scientist sensitivity ranged from 95.9% to
100% and specificity from 66.7% to 100% (e-Table 3).1013
Twenty-five cases remained “inconclusive” after review
by MDT (Table 3). These were difficult clinical
diagnostic cases that required further brushing and/or
additional diagnostic testing. The scientists reported a
similar number of samples as inconclusive (mean, 28
samples; range, 21-33) despite the fact that they had to
rely on HSVA images alone while the MDT had the full
range of clinical and diagnostic information at their
disposal (e-Table 3).
Two cases were classified as “PCD highly likely” by
both ERS guidelines and the MDT, but either “PCD
highly unlikely” or “inconclusive” by the HSVA
scientists (e-Table 3). The original clinical records
indicated that one patient had an isolated inner
dynein arm defect on TEM (ie, not a hallmark
abnormality) and five repeat brushings. Ciliary beat
frequency varied between low and normal on different
occasions and CBP was described as “almost normal”
in most brushing samples, some with observed
mucociliary clearance. Two of the HSVA scientists
classified this sample as “PCD highly unlikely” and
one deemed it “inconclusive.” The second patient had
normal nNO, TEM, and genetics for known causative
genes but was diagnosed as “PCD highly likely” based
on “semirotating” CBP coupled with the observation
of similar clinical symptoms and HSVA findings in
the patient’s sibling diagnosed with PCD. Two
scientists classified this sample as “highly unlikely,”
while one said it was “inconclusive.” Both patients are
currently treated as having PCD (ie, receiving care by
the PCD teams) but require further diagnostic testing
before a definite diagnostic outcome can be
determined.
Intra- and Interobserver Reliability
Using Fleiss k agreement to compare scoring between
the three scientists for each diagnostic outcome, we
found substantial agreement (k ¼ 0.70) for “PCD
positive” and moderate agreement (k ¼ 0.44) for “PCD
highly unlikely.” Agreement was low for “PCD highly
likely” (k ¼ 0.11) and “inconclusive” (k ¼ 0.20).21 The
combined agreement for the overall diagnostic outcomes
was moderate (k ¼ 0.42; 95% CI, 0.41-0.44).
The Cohen k agreement for intraobserver reliability was
k ¼ 0.70 (95% CI, 0.56-0.77) for scientist 1, k ¼ 0.66
(95% CI, 0.42-0.75) for scientist 2, and k ¼ 0.78
(95% CI, 0.61-0.85) for scientist 3. Importantly, none of
the scientists changed the outcome from their original
assessment from positive to negative or from negative to
positive (e-Table 4).1014 Original ResearchDiscussion
We have shown that HSVA has excellent accuracy and
interobserver reliability for diagnosing PCD, when
conducted by experienced scientists.
Accuracy of HSVA to Diagnose PCD
HSVA had excellent sensitivity and specificity to
diagnose PCD. With lack of a “gold standard” reference,
we used two imperfect references and found that
sensitivity and specificity were 100% and 96%,
respectively, when using diagnosis based on the ERS
guidelines as a reference, and 96% and 91% when using
the clinical diagnostic outcome as standard.
Independently analyzing 720 videos from 120 patients,
HSVA scientists correctly identified all “PCD positive”
cases using the ERS PCD guidelines as reference.
Considering that these patients have either a hallmark
TEM or pathogenic mutations, our findings suggest that
HSVA approaches 100% accuracy to detect clear-cut
PCD cases. If we were to consider those with an ERS-
defined “highly likely diagnosis” (ie, lack of hallmark
TEM or genetic confirmation but at least three HSVA
abnormal results or two abnormal results plus abnormal
ALI cell culture) as true PCD cases, we increase the
detection rate by 15% in our study population. This
increase matches the 15% to 20% PCD cases without a
hallmark TEM defect reported in the literature,
suggesting that HSVA can pick up cases that might have
been otherwise “missed” by TEM, particularly if used in
combination with nNO.2
Scientists reported two study samples as “highly unlikely”
or “inconclusive,”whereas bothMDT and ERS guidelines
had deemed the diagnostic outcome of the patients as
“PCD highly likely.” On further reviewing the diagnostic
history of these patients, the clinical decisions were based
on extensive repeat testing coupled with strong clinical
and family histories, highlighting the complexity of some
cases. Experts agree that some subtle beat pattern
abnormalities are difficult to spot by HSVA, even with
extensive training and years of experience.11 In addition,
secondary abnormities are common even in samples from
healthy individuals, highlighting the need for experienced
personnel analyzing the whole cilia strip to focus on the
overall findings.11,22-24 It is therefore not surprising that
in our study population, a high proportion of patients had
indeterminate outcomes according to both ERS
guidelines (35%) andMDTdecisions (21%). This was also
reflected in the number of “inconclusive” outcomes by the
scientists (23%). Sensitivity remained high even after
reclassification of “inconclusive” by HSVA to false[ 1 5 5 # 5 CHE ST MA Y 2 0 1 9 ]
TABLE 2 ] Aggregated Diagnostic Study Outcomes by Three Scientists Compared With Diagnostic Outcome
Defined by ERS PCD Diagnostic Guidelinesa
Study Outcomes by HSVA Scientists
Diagnostic Outcomes Based on ERS Guidelines
PCD Positiveb PCD Highly Unlikely PCD Highly Likely Inconclusive Total
PCD Positive 94 2 25 13 134
PCD Highly Unlikely 0 53 4 42 99
PCD Highly Likely 10 4 11 17 42
Inconclusive 4 19 8 54 85
Total 108 78 48 126 360
No. of Samples n ¼ 36 n ¼ 26 n ¼ 16 n ¼ 42 n ¼ 120
Numbers in bold contributed to the sensitivity and specificity calculations. HSVA ¼ high-speed video microscopy analysis. See Table 1 legend for expansion
of other abbreviations.
aSee Lucas et al2; n ¼ 360 scientists’ outcomes from 120 patient samples. “PCD positive” and “PCD highly unlikely” outcomes contributed to the accuracy
analyses. Individual scientists’ results are shown in e-Table 2.
b“PCD positive” cases were those with a hallmark transmission electron microscopy defect and/or genotype.negative. The drop in specificity is likely because the
scientists were less confident to rule out PCD based on
HSVA alone. This is expected, as scientists would
normally have additional information at their disposal,
and clinical decisions on whether to treat patients are
based on HSVA coupled with clinical and nNO data.
While the “worst-case scenario” calculations are
reassuring, reclassifying the inconclusive outcome was
probably overconservative because “inconclusive” is a
legitimate clinical outcome; it is difficult to consider
“inconclusive” as false positive or false negative,
particularly as the management pathway includes further
investigations for inconclusive outcomes.2
Reliability of HSVA to Diagnose PCD
We found high interobserver agreement for “PCD
positive” and moderate agreement for “PCD highly
unlikely” outcomes, as well as between pairs of scientists
(see the online article). “PCD highly likely” and
“inconclusive” had low agreement; this was due to the
interchangeability of these outcomes, as some scientistsTABLE 3 ] Aggregated Diagnostic Study Outcomes by Thre
Decision Made by MDT
Study Outcomes by HSVA Scientists
Diagnost
PCD Positivea P
PCD Positivea 151
PCD Highly Unlikely 4
Inconclusive 22
Total 177
No. of Samples n ¼ 59
n ¼ 360 scientists’ outcomes from 120 patient samples. “Inconclusive” outcom
are shown in e-Table 3. Numbers in bold contributed to the sensitivity and specifi
for expansion of other abbreviations.
aIncludes both “PCD positive” and “PCD highly likely” outcomes.
chestjournal.orgfelt more confident in assigning a “highly likely”
outcome while others adopted a more cautious option
(ie, “inconclusive”). In practice, samples labeled as
“highly likely” or “inconclusive” would both require a
repeat brushing from the patient and further testing.
We also found substantial intraobserver agreement of
samples reassessed by each of the scientists 1 year after the
original study outcome description. The fact that the
scientists were able to discriminate between positive and
negative outcomes, and agree on these between each other
and with their own initial assessment, is key as these two
extreme outcomes lead to different clinical management
plans. These demonstrate reliability amongst experienced
scientists when using HSVA to diagnose PCD.
Implications to Diagnostics and Clinical Practice
Following current guidelines, nasal brushings are taken
from every patient referred to a PCD diagnostic center
with a strong suspicion of PCD (ie, suggestive clinical
history). Samples can be evaluated by scientistse Scientists Compared With Original Diagnostic
ic Outcomes Based on Original Expert MDT Decision
CD Highly Unlikely Inconclusive Total
7 18 176
73 22 99
28 35 85
108 75 360
n ¼ 36 n ¼ 25 n ¼ 120
es were excluded from the accuracy analyses. Individual scientists’ results
city calculations. MDT ¼multidisciplinary team. See Table 1 and 2 legends
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experienced in HSVA on the day of testing. The nasal
sample is also sent for TEM analysis, but processing and
analyses take weeks. Our study demonstrates that
specialist scientists can reliably use HVSA to diagnose
some patients with PCD on the day of testing. This
provides the necessary evidence to counsel patients and
initiate lifelong treatment in a “one-stop clinic” with the
proviso that the final diagnostic outcome might change
once all test results are available. Additional tests such as
TEM, immunofluorescence, and genetic analysis will still
be needed to confirm the diagnosis2 and for deeper
phenotyping.7,25,26 The diagnosis remains inconclusive
for a high proportion of patients following isolated
HSVA, and these would need to wait for further
diagnostic results; it is notable that our study also
demonstrates that many patients have an indeterminate
outcome even following comprehensive testing, as
expected and discussed in the ERS PCD diagnostic
guidelines.2
Strengths and Limitations
This is the first blinded study to assess the accuracy and
reliability of HSVA to diagnose PCD. Previous literature
has called for standardized methodology and reporting
of diagnostic testing in PCD, in particular for
HSVA.2,3,9,11,23 In our study, diagnostic outcomes were
prospectively assigned by three experienced scientists.
Diagnostic outcomes were agreed a priori by the three
scientists and applied in a standardized manner when
independently scoring the video images.
However, our study has limitations. There is no “gold
standard” reference to diagnose PCD; so, despite the use
of combination testing as reference, we might have
missed “difficult to diagnose” PCD cases, likely classified
in this study as “inconclusive” by both MDT and the
ERS guidelines. A second limitation was the use of
HSVA in both comparator and the MDT reference;
therefore, in our comparison of HSVA with a positive
diagnosis according to ERS guidelines, we excluded
HSVA from the reference for sensitivity analyses as only
hallmark TEM and/or pathogenic mutations define a1016 Original Researchpositive diagnosis. We had limited genetic information
available for samples included in our study, which might
have confirmed some of the “highly likely” or
“inconclusive” cases as PCD. Equally, some of the
“highly likely PCD” patients might not have PCD.
Although we have good standardization of methods and
reporting in the UK, our protocols differ from those
used in many centers (eg, some centers measure HSVA
at room temperature while we analyze samples at 37C).
The use of disproportionate sampling allowed for the
selection of a higher proportion of positive cases without
having to review an unmanageable number of samples;
however, because of this approach, negative cases were
proportionally underrepresented. Fleiss k performs
poorly when the marginal classification probabilities are
either very small or very large, underestimating the
strength of agreement.27 In addition, k results rely on
arbitrary convention for what are considered substantial,
moderate, and low agreements. Therefore, we included
e-Tables 2-4 to provide data on individual scientist’s
performances.
The study scientists are highly experienced in
conducting HSVA. Accuracy and interobserver
reliability would probably be lower if conducted by
less experienced scientists. Scientists potentially
recognized cases, but this is unlikely due to high
diagnostic throughput and videos originating from
analyses conducted some time ago. While we have
demonstrated that it is technically reliable to provide
same-day provisional feedback based on HSVA, the
feasibility of achieving this will depend on local
resources.
In conclusion, we found that when following
standardized protocols HSVA has excellent sensitivity
and specificity to diagnose PCD. We found good
agreement between scientists on “PCD positive” and
“PCD highly unlikely” outcomes, confirming that HSVA
is a reliable diagnostic test. There is now a need for
international standardization of analysis and reporting
of HSVA.[ 1 5 5 # 5 CHE ST MA Y 2 0 1 9 ]
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